Seres Therapeutics (MCRB) Raw Materials (2023 - 2024)
Seres Therapeutics (MCRB) posted Raw Materials of $4.9 million for Q2 2024, up 16.81% sequentially from $4.2 million in Q1 2024, and up 802.01% YoY from $547000.0 in Q3 2023.
Seres Therapeutics (MCRB) Raw Materials (2023 - 2024) Analysis & Trends
Seres Therapeutics has reported Raw Materials for 2 years, with the latest figure at $4.9 million in Q2 2024.
- Quarterly Raw Materials rose 802.01% year-over-year to $4.9 million in Q2 2024, while the trailing twelve-month figure through Jun 2024 was $4.9 million (up 802.01% YoY) and the FY2023 annual result came in at $4.4 million, changed N/A from the prior year.
- Raw Materials grew to $4.9 million in Q2 2024 per MCRB's latest filing, from $4.2 million in the prior quarter.
- Over five years, Raw Materials peaked at $4.9 million in Q2 2024 and troughed at $547000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.72 Bn | 77.73 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.97 Bn | 36.87 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.53 Bn | 28.22 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Seres Therapeutics | 44.07 Mn | 44.07 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 4.93 Mn |
| Mar 31, 2024 | 4.22 Mn |
| Dec 31, 2023 | 4.43 Mn |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 547,000.00 |